nike a scris:Am facut doar doua din cele 3 doze de vaccin impotriva hepatitei b, a 3-a urmand sa o fac peste vreo luna din cate stiu eu.....Daca dupa a 2-a doza am intrat in contact cu o persoana care are hepatita B, este posibil sa iau si eu?
Poti sa faci si douazeci de vaccine ca nu o sa-ti aduca asbolut nimic bun si nici o protectie, ca daca ar fi asa nu ar mai avea nimeni hepatita. Nr. de hepatita insa a crescut exponential desi multi sunt vaccinatide hepatita.
Daca ar functiona vaccinul ar exista si un virus fotografiat la microscop electronic. Insa asa ceva nu exista inca.
Atunci cum se poate face un vaccin cu un virus care inca nu s-a descoperit inca si care in plus mai are si multe forme si care muteaza comtinuu..
Ce faci daca primesti hepatita A sau C sau D sau E ? Ca tu te-ai vaccinat numai de B !
Vezi, vaccinul e cam de pomana !
Dar sti oare ce substante se afla in vaccin ? Roaga-l pe doc sa-ti faca o copie de la hartia insotitoare
si intreaba-l ce substante toxice se afla in vaccin ca sa sti si tu ce ti se baga direct in sange.
Daca nu te poti uiti aici la un vaccin actual care se face in mai toate tarile si in romania.
Ambirix Vaccin de Hepatita A si B
http://www.emea.europa.eu/humandocs/PDFs/E...x/289402en1.pdf
Trebuie ca cineva sa fie de-a dreptul natang sa creada ca un singur virus de hepatita sa faca atatea boli diferite la atatea organe diferite .... de parca ar fi 1000 de virusi de la o mie de boli....
Este clar ca un virus de hepatita nu poate sa faca atatea: infectii, oboseala, gripa, meningita, boli de piele, de toate pt. toti.
De aceea nu vi se arata hartia insotitoare si nici nu vi se spune ce va apare cu siguranta dupa vaccin...
Mare tampit trebuie cineva sa fie sa creada ca un virus mort de hepatita care pana acum nici macar nu a fost vazut sau izolat vreodata sa faca o mie de boli diferite.. de la oboseala pana la gripa si boli de nervi.
Acest lucru il pot face numai otravurilel prezente in vaccin!
Nervous system disorders:
very common: headache
common: drowsiness
Gastrointestinal disorders:
common: gastrointestinal symptoms
Metabolism and nutrition disorders
very common: loss of appetite
General disorders and administration site conditions
very common: pain, redness, fatigue
common: swelling, fever
Psychiatric disorders:
very common: irritability/fussiness
Pain was reported following 50.7% of doses in the Ambirix group, as compared to 39.1% of doses
with the three dose combined vaccine. However, over the complete vaccination course, 66.4% of
subjects who received Ambirix reported pain, as compared to 63.8% of subjects who received the
three dose combined vaccine.
Fatigue was reported following 29.2% ( - 30% fac oboseala cronica ! ) - doses of Ambirix, as compared to 19.3% doses of the three
dose combined vaccine. However, the incidence of fatigue was similar based on a per subject analysis
(i.e. over the total vaccination course, 39.6% versus 36.2% of subjects for Ambirix and the three dose
vaccine respectively).
The incidence of pain and fatigue graded as severe was low and similar to that observed with the three
dose combined vaccine.
In a comparative trial in subjects aged 1-11 years, the incidences of local and general solicited
symptoms in the Ambirix group were similar to those seen with the three-dose combined vaccine
containing 360 ELISA Units of formalin inactivated hepatitis A virus and 10 micrograms of
recombinant hepatitis B surface antigen. The exception was a higher incidence of pain after Ambirix
in 6-11 year olds on a per dose basis, but not on a per subject basis.
The percentages of vaccinees reporting any solicited symptom graded as severe during a two-dose
regimen of Ambirix or a three dose regimen with the combined vaccine containing 360 ELISA Units
of formalin inactivated hepatitis A virus and 10 micrograms of recombinant hepatitis B surface
antigen, were not statistically different.
During post-marketing surveillance with the three dose combined vaccine containing either 360
ELISA Units of formalin inactivated hepatitis A virus and 10 micrograms of recombinant hepatitis B
surface antigen in a dose volume of 0.5 ml (recommended for subjects 1 year up to and including 15
years of age) or 720 ELISA Units of formalin inactivated hepatitis A virus and 20 micrograms of
recombinant hepatitis B surface antigen in a dose volume of 1 ml (recommended from the age of 16
years onwards), the following adverse reactions have been reported.
Investigations
abnormal liver function tests - Iti deregleaza ficatul !
Blood and lymphatic system disorders - Iti dergeleaza sangele
thrombocytopenia, thrombocytopenic purpura, lymphadenopathy
Nervous system disorders - Iti deregleaza nervii
syncope, dizziness, paresthesia, convulsions
Gastrointestinal disorders:
nausea, vomiting, diarrhoea, abdominal pain
Skin and subcutaneous tissue disorders
rash, pruritis, urticaria
Metabolism and nutrition disorders
decreased appetite
Vascular disorders
Hypotension
General disorders and administration site conditions
flu-like symptoms, fatigue
Immune system disorders
allergic reactions including anaphylactic and anaphylactoid reactions and serum sickness like disease
Following widespread use of the monovalent hepatitis A and/or hepatitis B vaccines, the following
adverse reactions have additionally been reported.
Nervous system disorders
multiple sclerosis, myelitis, facial palsy, polyneuritis such as Guillain-Barr
Se face intramuscular.Despre cresterea cazurilor de hepatita:eu zic sa se spele mai des lumea pe maini.Despre restul nu stiu ce sa zic nu cunosc.